Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema

Inclusion Criteria: * Diagnosis of non-ischemic diabetic macular edema with resulting reduction in visual functionality by determination of best corrected visual acuity (BCVA), ophthalmologic investigation, SD-OCT, FAG and anamnesis * BCVA between 0.05 and 0.6 or retinal thickness \> 300 µm determined by SD-OCT * The informed consent form must be signed before any study specific tests or procedures are done * Confirmation of the subject's health insurance coverage prior to the first screening visit * Age at least 18 years (inclusive) at the first screening visit * Ability to understand and follow study-related instructions Exclusion Criteria: * Severe ischemic maculopathy of the study eye * Active neovascularization of iris or retina in the study eye * History of intravitreal injection of VEGF-inhibitor or steroids in study eye within the last 3 month * Pathologies of the anterior segment of the study eye with reduced visual acuity (e.g. corneal opacification, advanced cataract) * Advanced glaucoma with central defects of the visual field in study eye * Retinal pathologies with reduced visus (e.g. central scars, age related macular degeneration) in study eye * Retinal vascular occlusion in medical history of study eye * Active or suspected ocular or periocular infections * Active intraocular inflammation in study eye * Intraocular surgery of study eye within the last 6 months * Laser therapy of study eye within the last 6 months * Systemic steroid therapy within the last 3 month * HbA1c \>10% * Systolic blood pressure above 170 mmHg and diastolic blood pressure above 110 mmHg (after at least 3 min in supine position) * Pregnant or breast-feeding woman and woman without adequate method of contraception. * Known hypersensitivity to the active substance or to any of the excipients